SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is experiencing a surge in trading volume and investor interest driven by unconfirmed market rumors regarding a potential acquisition by a large-cap biopharmaceutical company. The community remains divided, with long-term holders eyeing a potential buyout premium while others caution that the lack of official confirmation from the company or major outlets suggests the price action may be speculative volatility.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as a highly speculative meme coin, drawing intense division between traders gambling on its volatility and those warning of a potential pump-and-dump scheme. The community remains polarized, with some observing chart patterns and accumulation while others caution that the asset lacks utility and exhibits significant concentration among top holders.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund, trading as VCX, has experienced significant volatility and massive price premiums over its net asset value since its recent IPO, with investors heavily focused on its portfolio of private AI giants like Anthropic and SpaceX. Much of the community conversation is centered on the six-month lockup period affecting early shareholders, fueling heated debates between those holding for long-term growth and others bracing for a potential price correction.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is generating significant buzz as investors weigh upcoming earnings reports against expectations for a major NASA Lunar Terrain Vehicle (LTV) contract award. The community remains deeply divided, with bulls pointing to strong forward revenue guidance and long-term space infrastructure growth, while bears emphasize execution risks and the volatility associated with contract timing.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is experiencing significant price volatility following a post-earnings sell-off, triggering intense debate among investors over whether this is a technical gap-fill, temporary market noise, or a broader conspiracy regarding a potential low-cost acquisition by its distribution partner. While many in the community remain bullish on the brand's long-term growth and dominant shelf presence, others are actively expressing frustration with management and speculative concerns about corporate strategy.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly Inc. is experiencing intense volatility and community debate as traders grapple with a sharp post-earnings rally, heavy insider selling, and high short interest. While bulls highlight potential for long-term growth driven by AI and edge computing, bears argue the valuation is detached from fundamentals, leading to frequent clashes over technical resistance levels and short-squeeze potential.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is currently trending as investors react to a new shelf registration filing, sparking debate about potential financial stress versus strategic capital management. The community remains deeply divided, with some traders actively betting on a bullish breakout toward key resistance levels, while others highlight concerns over regulatory pressures, margin compression, and persistent downward price action.

Apollo Global Management, Inc. provides asset management services. It offers its clients excess return at every point along the risk-reward spectrum from investment grade to private equity with a focus on three business strategies: yield, hybrid, and equity. It operates through following segments: Asset Management, Retirement Services and Principal Investing. The Asset Management segment focuses on credit and equity investing strategies. The Retirement Services and Principal Investing segment consists of realized performance fee income, realized investment income from balance sheet investments, and certain allocable expenses related to corporate functions supporting the entire company. The company was founded by Marc Rowan in 1990 and is headquartered in New York, NY.

Apollo Global Management Inc

Apollo Global Management is currently in focus as investors analyze the firm's strategic positioning within the private credit sector and its potential for long-term growth driven by robust asset management inflows. The community is actively discussing the firm's ability to maintain performance amidst evolving macro conditions, while keeping a close watch on leadership insights regarding market stability and capital deployment strategies.

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

Personalis is trending as investor interest surges following the company's recent Medicare coverage approval for its NeXT Personal MRD test in breast cancer, a major milestone that removes a key barrier to commercial scaling. Community sentiment is overwhelmingly bullish, with active discussions focusing on the companys potential as a takeover target, its deep integration with Tempus AI, and the expected rapid revenue expansion as additional oncology indications secure regulatory reimbursement.

CBIZ, Inc. is a professional services advisor to middle market businesses and organizations nationwide. It offers its services in accounting, tax, advisory, benefits, insurance, and technology. The firm delivers forward-thinking insights and actionable solutions to help clients anticipate what's next and discover new ways to accelerate growth. It operates through the following segments: Financial Services, Benefits and Insurance Services and National Practices. The Financial Services segment offers accounting, tax, government health care consulting, financial advisory, valuation, and risk advisory services. The Benefits and Insurance Services segment includes group health benefits consulting, property and casualty brokerage, retirement plan services, and payroll. The National Practices segment deals with managed networking and hardware, and healthcare consulting. The company was founded by Michael G. DeGroote Sr. in 1987 and is headquartered in Independence, OH.

Cbiz Inc

Investors are actively debating the long-term outlook for CBIZ as the firm navigates integration challenges following major mergers. Discussions highlight concerns over recent financial performance and debt levels, while the community remains divided between those viewing the current valuation as an oversold opportunity and others wary of ongoing corporate headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oliver Luxxe Assets LLC Purchases New Position in Amneal Pharmaceuticals, Inc. $AMRX

Oliver Luxxe Assets LLC acquired a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 156,488 shares of the company's stock, valued at approximately $1...

Algert Global LLC Cuts Stock Position in Amneal Pharmaceuticals, Inc. $AMRX

Algert Global LLC decreased its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 8.7% during the 3rd quarter, according to its most recent 13F filing with the...

Capula Management Ltd Buys New Shares in Amneal Pharmaceuticals, Inc. $AMRX

Capula Management Ltd bought a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The...

Amneal Pharmaceuticals (NASDAQ:AMRX) Shares Down 5.5% - Here's What Happened

Amneal Pharmaceuticals (NASDAQ:AMRX) Shares Down 5.5% - Here's What Happened...

Amneal Pharmaceuticals Conference: Amneal 2.0 Targets 2026 Growth in Biosimilars, CREXONT and AvKARE Shift

Amneal Pharmaceuticals (NASDAQ:AMRX) used a recent investor presentation to highlight momentum coming out of fiscal 2025 and outline priorities for 2026 and beyond, emphasizing growth drivers across...

New Strong Buy Stocks for March 9th

ECG, AMRX, NESR, ACMR and HSY have been added to the Zacks Rank #1 (Strong Buy) List on March 9th, 2026.

Best Value Stocks to Buy for March 9th

AMRX, VET and NESR made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 9th, 2026.

Amneal Pharmaceuticals, Inc. $AMRX Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. raised its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 2.3% in the third quarter, according to the company in its most recent disclosure with the...

Short Interest in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Drops By 16.4%

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) saw a large drop in short interest in the month of February. As of February 13th, there was short interest totaling 10,600,098 shares, a...

Truist Financial Issues Positive Forecast for Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price

Truist Financial lifted their target price on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a "buy" rating in a report on Monday...

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

AMRX
Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AMRX News

AMRXAmneal Pharmaceuticals Inc - Ordinary Shares - Class A